Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Has Consensus Target Price of $5.55 According to Brokerages

Myriad Genetics, Inc. (NASDAQ:MYGN) has earned an average recommendation of “Hold” from the nine brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $5.55.

A number of research firms recently weighed in on MYGN. Piper Sandler upgraded Myriad Genetics from an “underweight” rating to a “neutral” rating and set a $5.00 price target on the stock in a research note on Tuesday, October 20th. Weiss Ratings lowered shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 27th. TD Cowen increased their price objective on shares of Myriad Genetics from $4.50 to $6.75 and gave the company a “hold” rating in a research report on Thursday. Wells Fargo & Company set a $4.50 target price on shares of Myriad Genetics in a report on Tuesday, October 20th. Finally, Leerink Partners upped their price target on shares of Myriad Genetics from $5.00 to $8.00 and gave the company a “market perform” rating in a research note on Thursday.

Hedge Funds Weigh In On Myriad Genetics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC bought a new stake in Myriad Genetics in the 1st quarter valued at $562,500,000. BlackRock Inc. bought a new position in Myriad Genetics during the 2nd quarter worth $62,184,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Myriad Genetics during the 2nd quarter worth $8,039,000. Man Group plc acquired a new position in shares of Myriad Genetics in the second quarter valued at about $5,189,000. Finally, Bank of America Corp DE acquired a new position in shares of Myriad Genetics in the second quarter valued at about $5,150,000. Institutional investors and hedge funds own 99.02% of the company’s stock.

Myriad Genetics News Summary

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, above analysts’ $191.33 million estimate, and a loss of $0.11 per share—narrower than the expected $0.20 loss. The company also raised the midpoint of its FY2026 revenue outlook to a range of $780 million–$790 million. Article: Myriad Genetics Raises FY26 Revenue Outlook Midpoint
• Positive Sentiment: TD Cowen raised its price target to $6.75 from $4.50, while retaining a Hold rating; Leerink Partners raised its target to $8 from $5, with a Market Perform rating. Higher targets suggest improved expectations, though neither firm upgraded its rating. Article: TD Cowen price target
• Neutral Sentiment: Myriad agreed to sell its Prenatal Health business for $210 million. The proceeds could support the company’s finances and focus, but the divestiture also changes its revenue base; the outlook is presented following the sale. Article: Myriad outlines 2026 outlook following divestiture
• Negative Sentiment: The company said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential exposure of sensitive information or disruption creates uncertainty and could be contributing to investor concern. Article: Myriad reports cybersecurity incident

Myriad Genetics Stock Down 5.9%

Shares of NASDAQ MYGN traded down $0.37 during trading hours on Friday, hitting $5.92. The company had a trading volume of 2,562,310 shares, compared to its average volume of 3,077,596. The stock has a market capitalization of $566.25 million, a P/E ratio of -4.35 and a beta of 1.62. The company has a quick ratio of 1.98, a current ratio of 2.21 and a debt-to-equity ratio of 0.40. Myriad Genetics has a 1-year low of $2.74 and a 1-year high of $8.09. The firm’s 50 day moving average is $4.50 and its 200-day moving average is $4.62.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 16.09%. The company had revenue of $202.70 million for the quarter, compared to analysts’ expectations of $191.33 million. On average, analysts expect that Myriad Genetics will post -0.99 earnings per share for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.